-
Twist Bioscience agrees to acquire Abveris for $190m
Pharmaceutical-Technology
November 24, 2021
Twist Bioscience has signed a definitive agreement to acquire in vivo antibody discovery services firm Abveris for up to $190m to boost its biopharma expertise.
-
Booster Shots Prompt Stronger, Longer Protection Than Original Shots: Study
Drugs
November 23, 2021
COVID-19 booster shots trigger much stronger and longer protection than full vaccination with two doses of the Pfizer or Moderna vaccines, according to a small study.
-
New Analyses of Two AZD7442 Covid-19 Trials Confirm Robust Efficacy and Long-Term Prevention in High-Risk Populations
AmericanPharmaceuticalReview
November 22, 2021
New data from the AZD7442 COVID-19 PROVENT prevention and TACKLE outpatient treatment Phase III trials both showed robust efficacy from a one-time intramuscular (IM) dose of the long-acting antibody (LAAB) combination.
-
Twist Bioscience Launches Revelar Biotherapeutics to Develop and Commercialize Novel COVID-19 and Other Antibody Therapeutics
ExpressPharma
November 19, 2021
Twist Bioscience Corporation has launched Revelar Biotherapeutics, Inc., an independently operated, new biotechnology company to develop and commercialize an antibody...
-
New analyses of two AZD7442 COVID-19 phase-III trials in high-risk populations confirm robust efficacy and long-term prevention
ExpressPharma
November 19, 2021
AstraZeneca yesterday said that new data from the AZD7442 COVID-19 Provent prevention and Tackle outpatient treatment phase-III trials showed robust efficacy from a one-time intramuscular (IM) dose of the long-acting antibody (LAAB) combination.
-
Twist Bioscience launches new company for Covid-19 antibody treatments
Pharmaceutical-Technology
November 17, 2021
Twist Bioscience has announced the formation of an independently operated biotechnology company, Revelar Biotherapeutics, which will develop and market new Covid-19 and other antibody therapies...
-
Validation Study Showcases Success of LSBD's Rapid SARS-CoV-2 Antibody Test
prnasia
November 16, 2021
The iQ Group Global Ltd (iQG Ltd) (NSX:IQG) on behalf of Life Science Biosensor Diagnostics Pty Ltd (LSBD), has announced the successful completion of a clinical validation study showcasing the efficacy...
-
Clinical Studies of PD-L1 Antibody ASC22 for HBV Functional Cure Selected for Inclusion in the "Best of The Liver Meeting's Summary" by AASLD Review Committee
prnasia
November 16, 2021
Ascletis Pharma Inc. (HKEX: 1672) announces today that Phase IIa and IIb clinical studies of PD-L1 antibody ASC22 (Envafolimab) for Hepatitis B Virus (HBV) functional cure have been selected for inclusion...
-
CStone Pharmaceuticals and DotBio sign a global discovery collaboration and option agreement to expand emerging portfolio of next-generation innovative therapeutics
prnasia
November 09, 2021
CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies...
-
Researchers discover new antibody that reduces severity of COVID-19 infection
ExpressPharma
November 05, 2021
Scientists have identified and tested an antibody that limits the severity of infections from a variety of coronaviruses, including those that cause COVID-19 as well as SARS.